HSBC cuts rating of UnitedHealth, citing earnings risks amid CEO shake-up

HSBC downgraded UnitedHealth (UNH) to "reduce" from "hold" and slashed its price target by 45% to $270, citing increased downside risk to 2025 earnings after the company suspended its full-year financial forecast and announced a leadership change with Stephen Hemsley replacing Andrew Witty as CEO due to higher-than-anticipated medical costs, particularly within its Medicare Advantage plans; shares were down over 1% premarket following the downgrade, adding to declines after the initial guidance withdrawal.

Analysis

UnitedHealth Group (UNH) is confronting significant headwinds to its earnings growth, as underscored by HSBC analysts who downgraded the stock to "reduce" from "hold" and drastically cut their price target by approximately 45% to $270. This action follows UNH's recent withdrawal of its 2025 financial guidance and an executive leadership change, with Andrew Witty stepping down as CEO and Stephen Hemsley, a former CEO (2006-2017) and current Chairman, taking the helm. The company cited a larger-than-anticipated increase in medical costs, particularly from new beneficiaries in government-backed Medicare Advantage plans, as the primary reason for suspending its outlook. This spike is attributed to accelerating care activity broadening to more benefit offerings than seen in Q1, and a general trend of more individuals, especially Medicare recipients, proceeding with elective surgeries deferred during the pandemic. The Optum Health division is also experiencing pressure from increased patient care needs. UNH shares reacted negatively, falling over 1% in premarket trading after the downgrade, compounding earlier declines. The company has also faced internal turmoil, including a shareholder lawsuit alleging a cover-up of operational impacts following the death of its insurance arm head, Brian Thompson. HSBC noted that the guidance cancellation increases downside risk for 2025 adjusted EPS and presents a "kitchen sinking opportunity" for the new CEO, potentially delaying recovery. InvestingPro's AI analysis further suggests UNH may not be significantly undervalued despite recent price declines.

Key Decisions for Investors

• Investors should acknowledge the heightened risk profile for UnitedHealth Group, evidenced by the substantial HSBC downgrade, withdrawn 2025 guidance, and ongoing medical cost pressures, potentially warranting a re-evaluation of existing positions.
• Monitor for announcements from the new CEO, Stephen Hemsley, regarding strategies to mitigate rising medical expenses and the eventual reinstatement of financial guidance, as these will be critical indicators for future performance.
• Consider the potential for continued share price volatility given the confluence of negative catalysts, including rising medical utilization, leadership transition, and the outstanding shareholder lawsuit concerning operational disclosures.